NOTE 10: - INTANGIBLE ASSETS, NET

On August 6, 2019, Corteva, through its subsidiary Pioneer Hi-Bred International, Inc., made an investment in the Company's agriculture biologicals subsidiary, Lavie Bio Ltd., which included the contribution of all Corteva’s holdings in its wholly owned subsidiary Taxon Biosciences, Inc. along with an amount of $10,000 in consideration for Lavie Bio Ltd.'s shares. This transaction included the following intangible assets (see also Note 17h):

	Pipeline Products		Potential Products		Microorganisms Collection		Total
Cost:

Balance on January 1, 2024	$	7,028	$	4,920	$	5,500	$	17,448

Balance on December 31, 2024	$	7,028	$	4,920	$	5,500	$	17,448

Accumulated Depreciation:

Balance on January 1, 2024	$	1,777	$	1,115	$	1,387	$	4,279

Amortization		405		255		314		974

Balance on December 31, 2024		2,182		1,370		1,701		5,253

Amortized cost on December 31, 2024	$	4,846	$	3,550	$	3,799	$	12,195

	Pipeline Products		Potential Products		Microorganisms Collection		Total
Cost:

Balance on January 1, 2023	$	7,028	$	4,920	$	5,500	$	17,448

Balance on December 31, 2023	$	7,028	$	4,920	$	5,500	$	17,448

Accumulated Depreciation:

Balance on January 1, 2023	$	1,374	$	862	$	1,072	$	3,308

Amortization		403		253		315		971

Balance on December 31, 2023		1,777		1,115		1,387		4,279

Amortized cost on December 31, 2023	$	5,251	$	3,805	$	4,113	$	13,169

Amortization expenses of intangible assets are classified in consolidated statements of profit or loss in research and development expenses, net.